Evaluation of Macular and choroidal Thickness measurements in HCV patients taking Recent anti viral hepatitis C Drugs (daclatasvir / sofosbuvir) Combination

Abstract Purpose This study aims to evaluate the effect of oral (sofosbuvir / daclatasvir) Combination on the macular and choroidal thickness of Egyptian patients with chronic hepatitis C virus infection using Optical Coherence Tomography (OCT) Methods This study was conducted on 30 subjects recruited from Viral Hepatitis Treatment and Research Centre and examined at Ophthalmology Out Patients Clinics, Ain Shams University Hospital during the period from June 2018 to February 2019. All participants underwent full general and ocular history taking and a precise ophthalmological clinical evaluation including assessment by OCT before starting our Direct Acting Antiviral Drugs (DAAs), sofosbuvir and daclatasvir (SOF/ DAC) combination for 12 weeks then, they reassessed again at the end of the treatment by Spectral Domain optical coherence tomography (SD –OCT) Retina Scan RS - 3000 advance(NIDEK Co., Gamagori Japan) (figure 1). Results Our study included 60 eyes of 30 patients with chronic hepatitis C with no evidence of changes on macular and choroidal thickness have been reported at 3 months after treatment onset in all subjects; the difference was statistically insignificant for macular and choroidal thickness. Conclusions Our study showed that all the participants who were followed before and after treatment showing that there were no changes on the best corrected visual acuity (BCVA), there were no changes on macular and choroidal thickness observed throughout all the study period.